表紙:ナノメディシンの世界市場:洞察、競合情勢、市場予測:2028年
市場調査レポート
商品コード
1397175

ナノメディシンの世界市場:洞察、競合情勢、市場予測:2028年

Nanomedicine - Market Insights, Competitive Landscape, and Market Forecast - 2028

出版日: | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.45円
ナノメディシンの世界市場:洞察、競合情勢、市場予測:2028年
出版日: 2023年12月18日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のナノメディシンの市場規模は、2023年から2028年までの予測期間中に11.39%のCAGRで拡大すると予測されています。ナノメディシンの需要は、主に心血管疾患、神経疾患、炎症性疾患、筋骨格系疾患などの様々な慢性疾患の有病率の増加によって後押しされています。さらに、政府の支援と資金提供の増加、副作用の少ない治療法に対する需要の急増、治療法の費用対効果、ナノ薬剤のアウトライセンシングの急増、診断と薬理効果のモニタリングのためのナノテクノロジーに基づく造影試薬の使用の増加などが、2023年~2028年の予測期間におけるナノメディシン市場の全体的な成長に寄与しています。

ナノメディシン市場は、さまざまな要因によって製品需要が伸びており、主要な要因の1つは、がん、心血管、神経などの慢性疾患の数値が上昇していることです。

例えば、世界保健機関(WHO)2022によると、2020年の乳がん罹患数は226万件、次いで肺がん221万件、結腸・直腸がん193万件、前立腺がん141万件、皮膚がん120万件、胃がん109万件となっています。

また、欧州委員会のデータベースによれば、2020年の欧州における女性のがん罹患率は191万2080人、男性は213万183人です。

ナノメディシンは、がん細胞や新生物に対して選択的に標的療法を提供し、臨床医はそこから化学療法、放射線療法、次世代の免疫療法や遺伝子療法を安全かつ効果的に腫瘍に投与することができます。ナノ医薬品は、その薬理作用を変化させ、作用部位の組織内分布を改善することにより、抗がん剤治療を改善することができます。したがって、がんの有病率の増加は、がんの治療や管理に使用されるナノメディシンの需要を増加させ、最終的にナノメディシン市場全体を推進します。

しかし、ナノメディシンの欠点、厳しい規制手続きなどがナノメディシン市場の成長を制限する可能性があります。

当レポートでは、世界のナノメディシン市場について調査し、市場の概要とともに、分子タイプ別、用途別、適応症別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 ナノメディシン市場レポートのイントロダクション

第2章 ナノメディシン市場のエグゼクティブサマリー

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 ナノメディシン市場の主な要因分析

  • ナノメディシン市場の促進要因
  • ナノメディシン市場の抑制要因と課題
  • ナノメディシン市場の機会

第5章 ナノメディシン市場におけるポーターのファイブフォース分析

第6章 ナノメディシン市場の概要

  • 分子タイプ別
  • 用途別
  • 適応症別
  • 地域別

第7章 ナノメディシン市場における企業と製品概要

  • Sanofi
  • Pfizer Inc.
  • Taiwan Liposome Company, Ltd.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Cytimmune Sciences, Inc.
  • Luminex Corporation
  • Merck & Co., Inc.
  • Starpharma Holdings Limited
  • Precision NanoSystems
  • Nanobiotix
  • Medtronic
  • Spago Nanomedical AB
  • Genetic Immunity
  • Nanospectra Biosciences

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Nanomedicine Market in Global (2020-2028)
  • Table 3: Nanomedicine Market in Global by Molecule Type (2020-2028)
  • Table 4: Nanomedicine Market in Global by Application (2020-2028)
  • Table 5: Nanomedicine Market in Global by Indication (2020-2028)
  • Table 6: Nanomedicine Market in Global by Geography (2020-2028)
  • Table 7: Nanomedicine Market in North America (2020-2028)
  • Table 8: Nanomedicine Market in the US (2020-2028)
  • Table 9: Nanomedicine Market in Canada (2020-2028)
  • Table 10: Nanomedicine Market in Mexico (2020-2028)
  • Table 11: Nanomedicine Market in Europe (2020-2028)
  • Table 12: Nanomedicine Market in France (2020-2028)
  • Table 13: Nanomedicine Market in Germany (2020-2028)
  • Table 14: Nanomedicine Market in the United Kingdom (2020-2028)
  • Table 15: Nanomedicine Market in Italy (2020-2028)
  • Table 16: Nanomedicine Market in Spain (2020-2028)
  • Table 17: Nanomedicine Market in the Rest of Europe (2020-2028)
  • Table 18: Nanomedicine Market in Asia-Pacific (2020-2028)
  • Table 19: Nanomedicine Market in China (2020-2028)
  • Table 20: Nanomedicine Market in Japan (2020-2028)
  • Table 21: Nanomedicine Market in India (2020-2028)
  • Table 22: Nanomedicine Market in Australia (2020-2028)
  • Table 23: Nanomedicine Market in South Korea (2020-2028)
  • Table 24: Nanomedicine Market in Rest of Asia-Pacific (2020-2028)
  • Table 25: Nanomedicine Market in the Rest of the World (2020-2028)
  • Table 26: Nanomedicine Market in the Middle East (2020-2028)
  • Table 27: Nanomedicine Market in Africa (2020-2028)
  • Table 28: Nanomedicine Market in South America (2020-2028)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Nanomedicine Market in Global (2020-2028)
  • Figure 3: Nanomedicine Market in Global by Molecule Type (2020-2028)
  • Figure 4: Nanomedicine Market in Global by Application (2020-2028)
  • Figure 5: Nanomedicine Market in Global by Indication (2020-2028)
  • Figure 6: Nanomedicine Market in Global by Geography (2020-2028)
  • Figure 7: Nanomedicine Market in North America (2020-2028)
  • Figure 9: Nanomedicine Market in the US (2020-2028)
  • Figure 10: Nanomedicine Market in Canada (2020-2028)
  • Figure 11: Nanomedicine Market in Mexico (2020-2028)
  • Figure 12: Nanomedicine Market in Europe (2020-2028)
  • Figure 13: Nanomedicine Market in France (2020-2028)
  • Figure 14: Nanomedicine Market in Germany (2020-2028)
  • Figure 15: Nanomedicine Market in the United Kingdom (2020-2028)
  • Figure 16: Nanomedicine Market in Italy (2020-2028)
  • Figure 17: Nanomedicine Market in Spain (2020-2028)
  • Figure 18: Nanomedicine Market in the Rest of Europe (2020-2028)
  • Figure 19: Nanomedicine Market in Asia-Pacific (2020-2028)
  • Figure 20: Nanomedicine Market in China (2020-2028)
  • Figure 21: Nanomedicine Market in Japan (2020-2028)
  • Figure 22: Nanomedicine Market in India (2020-2028)
  • Figure 23: Nanomedicine Market in Australia (2020-2028)
  • Figure 24: Nanomedicine Market in South Korea (2020-2028)
  • Figure 25: Nanomedicine Market in Rest of Asia-Pacific (2020-2028)
  • Figure 26: Nanomedicine Market in the Rest of the World (2020-2028)
  • Figure 27: Nanomedicine Market in the Middle East (2020-2028)
  • Figure 28: Nanomedicine Market in Africa (2020-2028)
  • Figure 29: Nanomedicine Market in South America (2020-2028)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0679

Nanomedicine Market By Molecule Type (Nanoparticle, Nanoshells, Nanotubes, And Nanodevices), Applications (Drug Delivery, Implants, Diagnostic Imaging, Biomaterials, And Others), Indication (Cardiovascular, Oncology, Neurology, Orthopaedic, Infectious, And Others), and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chronic diseases and the growing adoption of nanotechnology-based methods for drug delivery across the globe.

The global Nanomedicine market is estimated to grow at a CAGR of 11.39% during the forecast period from 2023 to 2028. The demand for nanomedicine is primarily being boosted by the increasing prevalence of various chronic diseases such as cardiovascular, neurological, inflammatory, musculoskeletal, and other diseases. Further, increased government backing and funding, the surge in demand for therapies with fewer side effects, and cost-effectiveness of therapies, the surge in nano drug out-licensing, and the increasing use of nanotechnology-based contrast reagents for diagnosis and monitoring of pharmacological effects, among others are thereby contributing to the overall growth of the nanomedicine market during the forecast period from 2023-2028.

Nanomedicine Market Dynamics:

The nanomedicine market is witnessing a growth in product demand owing to various factors, one of the key factors being the rising figures of chronic diseases such as cancers, cardiovascular, neurological, and others.

For instance, according to the World Health Organization (WHO) 2022, in 2020 the incidence of breast cancer was 2.26 million cases, followed by lung cancer with 2.21 million cases, colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, skin cancer 1.20 million cases, and stomach cancer with 1.09 million cases, globally.

Also, as per the database provided by the European Commission, the incidence of cancer among women in Europe in 2020 was 1,912,080 and in males was 2,130,183.

Nanomedicine offers target therapies selectively to cancerous cells and neoplasms, from which clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno and gene therapies to the tumour. Nanomedicines can improve anticancer therapy by changing their pharmacology and improving the distribution within the tissue at the site of action. Thus, the increasing prevalence of cancers will increase the demand for nanomedicine used in the treatment or management of cancer, ultimately propelling the overall market of nanomedicine.

The latest study done by Alzheimer's Disease International estimated that there were over 55 million people worldwide living with dementia in 2020. This number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050. There are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds. Nanomedicine is used for the treatment of central nervous system disorders. They are fabricated with features that control the drug delivery to the brain and increase efficacy. Polymeric micelles, with their unique properties, particle size, and shell structure, work as a drug delivery vehicle to the brain. Thus, with the increasing prevalence of neurological diseases such as dementia or Alzheimer's, the demand for nanomedicine will increase, thereby bolstering the overall market.

Additionally, market participants frequently develop new products to increase their visibility. For instance, in October 2020, Medtronic PLC unveiled their new Navigated Titanium Spinal Implant, the Adaptix Interbody System, including Titan nanoLOCK Surface Technology.

Therefore, the above-mentioned factors are contributing to the growth of the nanomedicine market during the forecast period from 2023-2028.

However, drawbacks of nanomedicine, stringent regulatory procedures, and others may restrict the nanomedicine market growth.

Nanomedicine Market Segment Analysis:

Nanomedicine Market by Molecule Type (Nanoparticle, Nanoshells, Nanotubes, and Nanodevices), Applications (Drug Delivery, Implants, Diagnostic Imaging, Biomaterials, and Others), Indication (Cardiovascular, Oncology, Neurology, Orthopaedic, Infectious, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the molecule type segment of the nanomedicine market, the nanoparticle category is expected to amass a significant revenue share in the year 2022. This was primarily owing to the benefits that various nanoparticles offer, as well as the growing usage of metal and metallic oxide particles in photodynamic therapy (PDT) for the treatment of infectious diseases and cancer.

Nanoparticles are spherical, polymeric particles composed of natural or artificial polymers. They range in size between 10 and 500 nm. As a consequence of their spherical shape and high surface area to volume ratio, these particles have a wide range of potential applications.

The nanoparticles are used in novel diagnostic instruments, imagery and methodologies, targeted medicinal products, pharmaceutical products, biomedical implants, and tissue engineering. They can be used for targeted drug delivery, hyperthermia, photoablation therapy, bioimaging, and biosensors. Nanoparticles are broadly classified into five categories, including metal, lipid, ceramic, polymeric, and semiconductor nanoparticles.

The nanoparticles used for drug delivery offer fewer side effects and reduce both dosage and dosage frequency. The nanoparticles can be used for the treatment of various diseases, such as cancer, cardiovascular, ocular, and central nervous system-related diseases.

Numerous businesses in this field are also working to create cutting-edge nanoparticle-based technology. For instance, NaNotics LLC and the Mayo Clinic began collaborating on research in January 2022 to create NaNot, a subtractive nanoparticle that selectively targets the soluble form of the immune inhibitor PD-L1, which is produced by tumours.

Thus, the above-mentioned factors are likely to propel the demand for nanoparticles, thereby contributing to the growth of the nanomedicine market during the forecast period from 2023-2028.

North America is expected to dominate the overall Nanomedicine Market:

Among all the regions, North America is estimated to account for the largest share in the Nanomedicine market in the year 2022. This domination is due to the increasing application of nanomedicine in early disease diagnosis, preventive intervention, and prophylaxis of chronic and acute disorders, the well-defined regulatory framework for the approval and commercialization of medicinal products, among others, will propel the market of nanomedicine in North America.

For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) 2023, it was stated that in 2021, about 1 in 20 adults age 20 and older have Coronary Artery Disease (CAD). Also, every year, about 805,000 people in the United States have a heart attack. This high burden may lead to the high demand for specific therapeutic nano vectors, nanostructured stents, and implants for tissue regeneration used during the treatment or management of cardiac diseases.

A number of the nation's major market players are also creating new items and technologies to rival those already on the market, while others are purchasing and collaborating with other businesses that are hot commodities. To market and launch Nanox's cutting-edge X-ray systems in Mexico, SPI Medical and Nano-X Imaging engaged in a distribution partnership in 2020. Cathode ray tubes in conventional machines are replaced by Nanox ARC using semiconductors and nanotechnology.

Further, in August 2020, Promimic's partner, Innovasis Inc., received the US FDA clearance to launch 3D-printed implants used in spinal fusion surgery. In addition, these implants use Promimic's Hanano Surface Technology, a bioactive nano treatment for implant device surfaces that leads to increased molecular anchoring of medical implants.

Thus, all the above-mentioned factors will lead to an increase in the North America nanomedicine market growth during the forecasting period of 2023-2028.

Nanomedicine Market Key Players:

Some of the key market players operating in the nanomedicine market include: Sanofi, Pfizer Inc., Taiwan Liposome Company, Ltd., Johnson & Johnson, Bristol-Myers Squibb Company, Cytimmune Sciences, Inc., Luminex Corporation, Merck & Co., Inc., Starpharma Holdings Limited, Precision NanoSystems, Nanobiotix, Medtronic, Spago Nanomedical AB, Genetic Immunity, Nanospectra Biosciences, and others.

Recent Developmental Activities in the Nanomedicine Market:

  • In March 2023, Moderna collaborated with Generation Bio to use its proprietary cell-targeted lipid nanoparticle delivery system for the development of non-viral genetic medicines to treat immune systems and liver-related disorders.
  • In March 2021, a collaboration between two Barcelona institutions and the Nanomedicine Lab at the University of Manchester received EUR 12 million in funding for the advancements in the European medical nanotechnology industry.
  • In October 2020, the Canadian government announced the funding of USD 18.2 million to Precision NanoSystems to develop an RNA vaccine for COVID-19. This investment will support the development of a cost-effective COVID-19 vaccine by using lipid-based drug delivery systems and nanomedicine.

Key Takeaways from the Nanomedicine Market Report Study:

  • Market size analysis for current nanomedicine market size (2022), and market forecast for 5 years (2023-2028)
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global nanomedicine market.
  • Various opportunities available for the other competitors in the nanomedicine market space.
  • What are the top-performing segments in 2022? How these segments will perform in 2028.
  • Which are the top-performing regions and countries in the current nanomedicine market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for nanomedicine market growth in the coming future?

Target Audience who can be benefited from this Nanomedicine Market Report Study:

  • Nanomedicine products providers
  • Research organizations and consulting companies
  • Nanomedicine-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in nanomedicine
  • Various End-users who want to know more about the nanomedicine market and the latest technological developments in the nanomedicine market.

Frequently Asked Questions for the Nanomedicine Market:

1. What is nanomedicine?

  • Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs. Nanomedicine also known as healthcare nanotechnology includes products that are nanoformulations of the existing drugs or new drugs, or nanomaterials.

2. What is the market for global nanomedicine?

  • The global Nanomedicine market is estimated to grow at a CAGR of 11.39% during the forecast period from 2023 to 2028.

3. What are the drivers for the global nanomedicine market?

  • The demand for nanomedicine is primarily being heightened by the growing burden of chronic diseases, rising developments and recent commercialization of products, such as mRNA and liposome-based vaccines, growing adoption of nanotechnology-based methods for drug delivery and the prevalent inefficiency of conventional therapeutics, and increasing out-licensing of nano drugs among others, thereby contribute to the overall growth of the nanomedicine market during the forecast period from 2023-2028.

4. Who are the key players operating in the global nanomedicine market?

  • Some of the key market players operating in the nanomedicine market include Sanofi, Pfizer Inc., Taiwan Liposome Company, Ltd., Johnson & Johnson, Bristol-Myers Squibb Company, Cytimmune Sciences, Inc., Luminex Corporation, Merck & Co., Inc., Starpharma Holdings Limited, Precision NanoSystems, Nanobiotix, Medtronic, Spago Nanomedical AB, Genetic Immunity, Nanospectra Biosciences, and others.

5. Which region has the highest share in the nanomedicine market?

  • North America is expected to dominate the overall nanomedicine market during the forecast period from 2023-2028. Factors such as the presence of expanding partnerships between businesses working in this area and nanomedicine start-up companies, technology improvements along with applicable applications in early illness detection, preventative intervention, various R&D efforts on nanotechnology-based medications and diagnostics, increase in the number of health facilities coupled with smart instruments, and adoption of advanced technologies of nanomedicines among others will positively impact the North American nanomedicine market.

Table of Contents

1. Nanomedicine Market Report Introduction

2. Nanomedicine Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Nanomedicine Market Key Factors Analysis

  • 4.1. Nanomedicine Market Drivers
    • 4.1.1. Growing burden of chronic diseases such as cancers, cardiovascular, genetic, and others
    • 4.1.2. Increasing advancements in nanoscale technologies for diagnostic procedures
    • 4.1.3. Growing preference for personalized medicines
  • 4.2. Nanomedicine Market Restraints and Challenges
    • 4.2.1. Drawbacks of Nanomedicine
    • 4.2.2. Stringent Regulatory Procedure
  • 4.3. Nanomedicine Market Opportunities
    • 4.3.1. Increasing demand for smart pills and nanobots
    • 4.3.2. Surging research on nano-sensors for the detection of chemicals and pathogens

5. Nanomedicine Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Nanomedicine Market Layout

  • 6.1. By Molecule Type
    • 6.1.1. Nanoparticle
    • 6.1.2. Nanoshells
    • 6.1.3. Nanotubes
    • 6.1.4. Nanodevices
  • 6.2. By Applications
    • 6.2.1. Drug Delivery
    • 6.2.2. Implants
    • 6.2.3. Diagnostic Imaging
    • 6.2.4. Biomaterials
    • 6.2.5. Others
  • 6.3. By Indication
    • 6.3.1. Cardiovascular
    • 6.3.2. Oncology
    • 6.3.3. Neurology
    • 6.3.4. Orthopaedic
    • 6.3.5. Infectious
    • 6.3.6. Others
  • 6.4. By Geography
    • 6.4.1. North America Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.1.1. United States Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.1.2. Canada Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.1.3. Mexico Nanomedicine Market Size in USD million (2020-2028)
    • 6.4.2. Europe Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.2.1. France Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.2.2. Germany Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.2.3. United Kingdom Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.2.4. Italy Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.2.5. Spain Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.2.6. Rest of Europe Nanomedicine Market Size in USD million (2020-2028)
    • 6.4.3. Asia-Pacific Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.3.1. China Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.3.2. Japan Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.3.3. India Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.3.4. Australia Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.3.5. South Korea Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.3.6. Rest of the Asia-Pacific Nanomedicine Market Size in USD million (2020-2028)
    • 6.4.4. Rest of the World (RoW) Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.4.1. Middle East Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.4.2. Africa Nanomedicine Market Size in USD million (2020-2028)
      • 6.4.4.3. South America Nanomedicine Market Size in USD million (2020-2028)

7. Nanomedicine Market Company and Product Profiles

  • 7.1. Sanofi
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Pfizer Inc.
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Taiwan Liposome Company, Ltd.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Johnson & Johnson
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Bristol-Myers Squibb Company
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Cytimmune Sciences, Inc.
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Luminex Corporation
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Merck & Co., Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Starpharma Holdings Limited
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Precision NanoSystems
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Nanobiotix
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Medtronic
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Spago Nanomedical AB
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Genetic Immunity
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Nanospectra Biosciences
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us